

VIRUSES VACCINES AND ERADICATION

Thursday 6 June 2019
QEII Centre, London

With thanks to our conference sponsors



INTRODUCTION

Welcome to the inaugural Viruses Vaccines and Eradication Conference at the QEII Centre in Westminster, London. The conference centre provides all the facilities required for our delegates.

We are honoured that a number of eminent speakers have confirmed participation and will share their work with us.

We are delighted to have been able to offer reduced registration rates for scientists and clinicians in training, and also for members of our collaborating organisations.

We would like to thank each of our speakers for their invaluable contribution in helping to make the meeting what we hope will be a great success. Finally, we would like to thank all of our sponsors and exhibitors for their support of the meeting. Sponsors have no involvement in the content or the selection of speakers in the programme.

We hope that you enjoy the meeting and find it of relevance to both your educational and your practical needs.

Yours Sincerely

Organising Committee



Professor
Graham Foster

Queen Mary's, University
of London and Barts Health
NHS Trust, London



Professor
Anna Maria Geretti

University of Liverpool, UK



Professor
Paul Griffiths

University College London, UK



Professor
Margaret Johnson

Royal Free London
NHS Foundation Trust,
UK and Royal College of
Physicians, London



Continuing Professional Development (CPD)

Medical staff in career-grade posts who are enrolled with one of the Federations of Royal Colleges for Continuing Professional Development can receive CPD credits at the rate of one CPD credit per hour (exclusive of travel, refreshments or social activities). Certificates for attendance will be supplied in the conference pack that will be handed to you at the registration desk.

PROGRAMME


0900-1700	<i>Registration and exhibition open</i>
0900-0905	Welcome and introduction Professor Anna Maria Geretti, <i>University of Liverpool</i>
0905-0950	What does success look like? Chair: Professor Paul Griffiths, <i>University College London</i>
0905-0925	Global rinderpest eradication: a triumph for animal health, a great benefit to human health Dr Michael Baron, <i>The Pirbright Institute</i>
0925-0945	Is eradication of poliomyelitis in sight? Professor David Salisbury, <i>Chair, WHO Global Commission for the Certification of Poliomyelitis Eradication</i>
0945-0950	Q&A
0950-1015	Keynote lecture <i>Offered in association with The BMJ STI Journal and BASHH</i> Chair: Dr Olwen Williams, <i>Betsi Cadwaladr University Health Board, Wales</i>
0950-1010	Will vaccination eliminate HPV disease? Dr Richard Gilson, <i>University College London</i>
1010-1015	Q&A
1015-1040	Morning Coffee
1040-1210	HIV: a paradigm of disease control? Chair: Professor Margaret Johnson, <i>Royal Free London NHS Foundation Trust</i>
1040-1055	Clinical Case 1 Dr Rachel Herbert, <i>North Middlesex University Hospital</i>
1055-1120	Have we won the clinical battle against HIV drug resistance? Moderator: Professor Anna Maria Geretti The case for Dr Ana Milinkovic, <i>Chelsea and Westminster Hospital, London</i> The case against Dr Tristan Barber, <i>Royal Free London NHS Foundation Trust</i>
1120-1140	The myth or reality of an HIV cure: give us hope! Professor Sarah Fidler, <i>Imperial College Healthcare NHS Trust, London</i>
1140-1210	Panel debate: What does the future hold for HIV? Dr Tristan Barber, <i>Royal Free London NHS Foundation Trust</i> Dr Ana Milinkovic, <i>Chelsea and Westminster Hospital, London</i> Mr Simon Collins, <i>HIV i-Base</i> Professor Sarah Fidler, <i>Imperial College Healthcare NHS Trust, London</i> Professor Anna Maria Geretti, <i>University of Liverpool</i> Dr Olwen Williams, <i>Betsi Cadwaladr University Health Board, Wales</i>
1210-1320	Focus on hepatitis C Chair: Mrs Fiona Marra, <i>University of Liverpool</i>
1210-1220	Clinical Case 2 Dr Brendan Healy, <i>University Hospital of Wales, Cardiff</i>

PROGRAMME

1220-1240	Latest guidance on hepatitis C drug resistance Dr Daniel Bradshaw, <i>Public Health England</i>
1240-1300	Is elimination of hepatitis C in sight for the UK? Professor Graham Foster, <i>Queen Mary's, University of London and Barts Health NHS Trust</i>
1300-1320	Panel debate: Hepatitis C in the UK: successes, challenges, and opportunities Dr Sanjay Bhagani, <i>Royal Free London NHS Foundation Trust</i> Dr Daniel Bradshaw, <i>Public Health England</i> Professor Graham Foster, <i>Queen Mary's, University of London and Barts Health NHS Trust</i> Dr Brendan Healy, <i>University Hospital of Wales, Cardiff</i> Mrs Fiona Marra, <i>University of Liverpool</i> Dr Emma Thomson, <i>University of Glasgow Centre for Virus Research</i>
1320-1410	<i>Lunch and networking</i>
1410-1515	Focus on hepatitis B Offered in association with BASL / BVHG Chair: Dr Shevanthi Nayagam, <i>Imperial College London</i>
1410-1430	Theoretical opportunities and practical limitations of seeking to eradicate hepatitis B Dr Patrick Kennedy, <i>Queen Mary's, University of London and Barts Health NHS Trust</i>
1430-1450	Novel hepatitis B biomarkers for profiling and guiding management Professor Florian van Boemmel, <i>University of Leipzig, Germany</i>
1450-1515	Panel debate: What stands in the way of eliminating hepatitis B? Professor Florian van Boemmel, <i>University of Leipzig, Germany</i> Dr Patrick Kennedy, <i>Queen Mary's, University of London and Barts Health NHS Trust</i> Dr Shevanthi Nayagam, <i>Imperial College London</i> Dr Ivana Carey, <i>King's College Hospital, London</i>
1515-1540	<i>Afternoon tea</i>
1540-1615	Focus on hepatitis B continued Chair: Dr Shevanthi Nayagam, <i>Imperial College London</i>
1540-1550	Clinical Case 3 Dr Giovanni Villa, <i>Brighton and Sussex Medical School</i>
1550-1610	Forgotten, not gone: Hepatitis Delta in the world Dr Alexander Stockdale, <i>University of Liverpool on behalf of the Delta Study Group</i>
1610-1615	Q&A
1615-1655	The future Chair: Professor David Salisbury, <i>Chair, WHO Global Commission for the Certification of Poliomyelitis Eradication</i>
1615-1635	The next candidate for eradication: Is measles on your list? Dr Kevin Brown, <i>Public Health England</i>
1635-1650	An emerging threat or sporadic events? Monkey pox Dr Paul Hine, <i>Royal Liverpool University Hospital</i>
1650-1655	Q&A
1655-1700	Summary and close Professor Paul Griffiths, <i>University College London</i>

EXHIBITION FLOOR PLAN

Westminster Suite, Fourth Floor



SPEAKER BIOGRAPHIES

Dr Tristan Barber is a consultant in HIV Medicine at the Ian Charleson Day Centre, Royal Free Hospital, London. He has a research background in Phase III drug trials, HIV vaccine studies and HIV-related neurocognitive impairment. He is currently Chair of both the BASHH HIV/BBV Specialist Interest Group and the BHIVA International Partnerships Working Group.

Dr Michael Baron studied at Cambridge University, and completed his PhD at St Thomas' Hospital, London. He worked at Cambridge and Leicester universities and the Karolinska Institute, Sweden, before settling at the Institute for Animal Health, Pirbright, UK (now The Pirbright Institute), where he has spent more than 25 years studying rinderpest virus, peste des petits ruminants virus and Nairobi sheep virus.

Dr Mike Beadsworth is a consultant in the Royal Liverpool University Hospital's (RLUH) tropical and infectious diseases unit (TIDU). He is also an honorary senior lecturer at the University of Liverpool and an honorary clinical Fellow in the Liverpool School of Tropical Medicine. He is clinical director of specialist and academic medicine, including TIDU. He is the RLUH lead for the national high consequence infectious disease programme.

Dr Sanjay Bhagani is a consultant physician and an honorary associate professor of infectious diseases and HIV medicine at the Royal Free Hospital. He is the current Vice-President of the European AIDS Clinical Society, and Co-Chair of the EACS Hepatitis and Liver Disease Guidelines Panel.

Dr Dan Bradshaw is a consultant in the Virus Reference Department, National Infection Service, Public Health England. He trained as a genitourinary medicine physician and has an interest in HIV and viral hepatitis. Dan also chairs PHE's HCV Resistance Group.

SPEAKER BIOGRAPHIES

Dr Kevin Brown is a consultant medical virologist within the Immunisation and Countermeasures Department in Public Health England. As part of his responsibilities he heads the Immunisation and Diagnosis Unit, which has a primary interest in vaccine-preventable viral infections and is one of the WHO Global Laboratories for Measles and Rubella. His current areas of interest include parvoviruses, measles, mumps, rubella, VZV, rabies and all aspects of virus discovery and newly emerging viruses.

Dr Ivana Carey is Clinical Lecturer in Viral Hepatitis at King's College Hospital with the special interest in HBV infection - namely new non-invasive biomarkers and their clinical utility in diagnosis and management; HBV in children and prevention of mother-to-child transmission and HBV/HDV co-infection.

Simon Collins is a person living with HIV and a treatment advocate at HIV i-Base (www.i-Base.info). He edits HIV Treatment Bulletin and a range of non-technical guides to HIV treatment. He also encourages people living with HIV to take an active role in their own health.

Professor Sarah Fidler began working with people living with HIV from 1992 and completed her clinical training in HIV and GUM. During her training she completed a PhD in HIV immunology at Imperial College London. She has a clinical research background, and is currently working at Imperial College London and Imperial College NHS Trust as a professor and consultant physician in HIV medicine. Her areas of special research interest are in HIV intervention trials, from leading the three-arm randomised controlled strategic intervention in Primary HIV infection trial (SPARTAC) funded by the Wellcome Trust. This study reported in 2011 and was published in *N Eng J Med* in 2013. Subsequently, she lead and co-chaired the UK-based collaboration: CHERUB of clinicians, community representatives and scientists, enrolling people living with treated HIV into cure studies, both observational and interventional. This collaboration is supported by NIHR BRC funding. More recently she has completed the MRC funded RIVER trial, the first randomised study comparing a kick and kill approach to HIV versus ART-only in primary HIV acquisition. She is Co-Chair of the HPTN071 (PopART) trial the largest HIV prevention trial in sub-Saharan Africa testing a combination HIV prevention trial with standard care, the results recently presented at the CROI conference in Seattle.

Professor Graham Foster leads the Barts Health Liver Centre and is the NHSE national clinical lead for HCV.

Professor Anna Maria Geretti - MD, PhD, FRCPath - is Professor of Virology and Infectious Diseases at the University of Liverpool and consultant in infectious diseases at the Royal Liverpool University Hospital. She also consults for the Clinical Trial Unit of the Brighton & Sussex Medical School and is Editor-in-chief of the *BMJ Sex Transm Infect* journal. Anna Maria's clinical and research interests focus on HIV and viral hepatitis. Her experience includes antiviral drug development within industry, epidemiology research with the World Health Organization, and research programmes in sub-Saharan Africa. Her research is primarily aimed at translational applications and has led to over 250 peer-reviewed articles, editorials, reviews, and book chapters. Her ambition is to turn her multifaceted experience into delivery of an impact that promotes progress of medicine and science and is globally beneficial to public health and patient care.

Dr Richard Gilson is Director of the Centre for Clinical Research in Infection and Sexual Health and Deputy Director of the Institute for Global Health at UCL. His research includes a programme of work on HPV infection covering prevention of infection in men who have sex with men, screening and early detection to prevent anal cancer, and treatment of anogenital warts. The work is funded by NIHR and Cancer Research UK.

Professor Paul Griffiths is Professor of Virology at University College, London. He is Editor-In-Chief of *Reviews in Medical Virology*. His research concerns cytomegalovirus infection, where he has helped to define the natural history and pathogenesis of this infection and used this information to design randomised controlled trials of antiviral drugs and prototype vaccines.

Dr Brendan Healy has been a consultant in microbiology and infectious diseases at the University Hospital of Wales, Cardiff, UK since 2007. He is the Lead for the Blood Borne Viral Hepatitis Action Plan for Wales, BBV lead for Cardiff and Vale, Chair of the Viral Hepatitis subgroup of the All Wales Liver Disease Implementation Group and Lead clinician for the All Wales Hepatitis Network and All Wales Hepatitis C roll-out programme.

Dr Paul Hine is an infectious diseases registrar from Liverpool.

Professor Margaret Johnson has been the holder of MRC, Wellcome and NIHR grants throughout her career. She has also worked with the pharmaceutical industry and been Principal Investigator on in excess of 150 phase II/III registrational studies. The latter brings in an annual income of approximately £400,000, which is used to fund clinical research fellows and research nurses. Over the past 15 years this has generated funds of £7 million. She currently has nine studies open for recruitment, 23 studies being followed up, five new studies in set up and three new studies for which feasibility forms have been completed. She has published 520 papers in peer reviewed journals and supervised eight PhD/MD theses. She has two current PhD students. She has been an invited speaker at major national and international conferences over the past 20 years. She has lectured in the US, Canada, France, Italy, Spain and the UK over the past 2 years. She has a lifetime H-Index of 71 and a 5 year H-Index of 14.

SPEAKER BIOGRAPHIES

Dr Patrick Kennedy is a reader and consultant hepatologist at Barts and London School of Medicine and Dentistry. His primary focus is translational research in hepatitis B virus (HBV) combined with a special interest in HBV in young people. He set up and runs a dedicated young adult clinic at Royal London Hospital and leads the HBV service at Barts Health. He has produced novel work redefining disease phase in HBV, challenging treatment candidacy in chronic hepatitis B (CHB). Developing these research avenues, the focus of his current work is on individualised treatment strategies for CHB and changing current management paradigms. He leads the UK special interest group (SIG) in HBV, is an expert advisor for NICE and a member of the viral hepatitis clinical guideline committee for CHB. He provides expert opinion for the United Kingdom Advisory Panel on blood-borne viruses and is the hepatology lead for the Gastroenterology and Hepatology Section at the Royal Society of Medicine. He is also the chief/principal investigator for a number of investigator-led and commercial Phase I, II and III, clinical trials of novel HBV therapies.

Mrs Fiona Marra is the lead pharmacist for the Liverpool HIV and Hepatitis drug interactions websites for the University where she writes the content and is also completing a clinical pharmacology PhD. Her clinical work is in Glasgow where she is lead clinician of paediatric ID and senior pharmacist for adult HIV/HCV. She was an author of the 2018 EASL recommendations for the treatment of HCV and sits on the BHIVA Hepatology group amongst others.

Dr Ana Milinkovic is Clinical Trial Physician in Chelsea and Westminster Hospital, UK. She received her MD at the Medical University of Belgrade. She initially trained in infectious diseases in Belgrade and subsequently in the Hospital Clinic Barcelona. She had received her PhD for investigations of the mitochondrial, cellular and organ toxicities of antiretroviral drugs. Her research interests include the clinical development of new ARVT, PEP and PrEP, and metabolic and morphologic complications of HIV disease and ageing. She has published and presented widely.

Dr Shevanthi Nayagam is a clinical lecturer and hepatologist at Imperial College London. Her multidisciplinary research combines clinical field research and the use of applied modelling and health economics in guiding public health policy towards the elimination of viral hepatitis. Her research aims to better understand the epidemiology of viral hepatitis and how to scale up delivery of hepatitis prevention and treatment interventions in the most effective and cost-effective way, primarily in Africa and Asia. She is a research member of the PROLIFICA project (Prevention of Liver Disease and Cancer in Africa), a large-scale community hepatitis B virus (HBV) screening and treatment programme in the Gambia and Senegal and has research projects in Ethiopia. She has been collaborating with the World Health Organization since 2012 and is a member of the Vaccine Impact Modelling Consortium. She has also been invited by several countries (including Senegal, South Africa and China) to support their national hepatitis strategies.

Dr Emma Thomson is a clinical senior lecturer in infectious diseases in Glasgow where she runs the HCV-HIV treatment service. She is Vice-Chair of the BHIVA hepatitis expert group and a member of the WHO HCV treatment guidelines committee. Her laboratory focuses on next generation sequencing of HCV and other viruses. The lab has recently identified several novel HCV strains that may be resistant to some DAA therapies.

Professor David Salisbury was Director of Immunisation at the Department of Health, London, until 2014 responsible for the national immunisation programme. He continues to work extensively with the WHO on the Global Programme for Vaccines. He was the Chair of the WHO Strategic Advisory Group of Experts on Vaccines 2005 to 2010. He is Chair of the Global Commission for Certification of Poliomyelitis Eradication and Chair of the Board of the Jenner Vaccine Foundation. Professor Salisbury was made a Companion of the Order of the Bath in the Queen's Birthday Honours, 2001, for his services to immunisation. He is an associate fellow at the Centre on Global Health Security, Royal Institute of International Affairs, Chatham House, London.

Dr Alexander Stockdale is a Wellcome Trust Clinical PhD fellow. He is currently working on hepatitis B research in Malawi at the Malawi-Liverpool-Wellcome Trust Clinical Research Programme and has been an honorary consultant physician at the Queen Elizabeth Central Hospital in Blantyre for over 2 years. He is interested in the epidemiology and virology of hepatitis B and D.

Dr Giovanni Villa is an infectious diseases specialist trained in Italy and currently a clinic research fellow in the UK. His academic interests are varied and include determinants of outcomes of HIV infection and treatment, with a specific interest in comorbidities (diabetes, hypertension, chronic renal disease), psychosocial and mental health aspects, and co-infection with viral hepatitis. His research is based both in the UK and in sub-Saharan Africa (Ghana).

Dr Olwen Williams is President of BASHH and Vice President of the Medical Women's Federation. She has held senior leadership roles, as well as her consultant post in sexual health/HIV at Betsi Cadwaladr University Health Board in North Wales.

Journal of Virus Eradication

Call for papers

We are seeking papers for forthcoming issues of the Journal. We welcome original research, reviews, viewpoints or blogs.

Please submit your articles via our website (www.viruseradication.com)

- We include papers on epidemiological, immunological, virological, pharmacological, pre-clinical and *in vitro* research that highlight work in the rapidly developing field of virus eradication
- All content can be found in PubMed Central and is indexed by PubMed
 - No publication charges for authors

Editor-in-Chief

Jintanat Ananworanich

Associate Director for Therapeutics Research,
US Military HIV Research Program, USA

Editors

Margaret Johnson

Professor of HIV Medicine, University College Medical School,
Royal Free London NHS Foundation Trust, UK

Sabine Kinloch-de Loës

Senior Lecturer, Division of Infection and Immunity
University College London, UK

Editorial Board

Nicolas Chomont (Canada) • Steven Deeks (USA) • Geoff Dusheiko (UK) • Sarah Fidler (UK)
Paul Griffiths (UK) • Alain Lapeyrolle (France) • Nelson Michael (USA)
Jürgen Rockstroh (Germany) • Irini Sereti (USA) • Janet Siliciano (USA)
Robert Siliciano (USA) • Guido Silvestri (USA) • Linos Vandekerckhove (Belgium)

www.viruseradication.com

E: editorial@viruseradication.com